Please login or register first to view this content.
Oncology Resource Center
Drug Monographs
Click on the subsection below to see prescribing information
- Bladder, kidney, and other urologic cancers
- Bone and connective tissue cancer
- Breast cancer
- CNS cancer
- Colorectal and other GI cancers
- Cytoprotective and supportive care agents
- Eye cancer
- Gynecologic cancer
- Head and neck cancer
- Kaposi’s sarcoma
- Leukemias, lymphomas, and other hematologic cancers
- Melanoma and other skin cancers
- Pancreatic, thyroid, and other endocrine cancers
- Prostate and other male cancers
- Respiratory and thoracic cancers
- Solid tumors
NEWS & FEATURES
Adjuvant Therapy Recommendations for Breast Cancer Drop Between Ages 69 and 70
NSCLC Survival Improved With FDG PET/CT Imaging Before Radiation Therapy
Trodelvy Approved for Pretreated HR+/HER2- Metastatic Breast Cancer
January 2023: Notable Drug Approvals
Turalio Dosing Regimen Updated for Tenosynovial Giant Cell Tumor
Orserdu Approved for ER+, HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
Jaypirca Approved for Relapsed/Refractory Mantle Cell Lymphoma
Keytruda Approved as Adjuvant Treatment for Stage IB, II, or IIIA NSCLC
Trial Evaluating Lisocabtagene Maraleucel for Relapsed/Refractory CLL Meets Endpoint
Trial Investigating Pembrolizumab for Hormone-Sensitive Prostate Cancer Discontinued
Avapritinib Gets Priority Review for Indolent Systemic Mastocytosis
Effectiveness of Corticosteroids in Treating Chemotherapy-Induced Thrombocytopenia
Follow-Up Colonoscopy Rates Low After Positive Stool-Based Test
Brukinsa Gains Approval for Chronic Lymphocytic Leukemia
Risk for Advanced Neoplasm Low 10+ Years After Negative Colonoscopy
Tukysa Combo Approved for RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer
Immunotherapy Combo Reduces Risk of Cancer Recurrence in Early-Stage Liver Cancer
Prostate Cancer ADT Increases Bone Fracture Risk
